ATE331503T1 - Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe - Google Patents

Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe

Info

Publication number
ATE331503T1
ATE331503T1 AT96930337T AT96930337T ATE331503T1 AT E331503 T1 ATE331503 T1 AT E331503T1 AT 96930337 T AT96930337 T AT 96930337T AT 96930337 T AT96930337 T AT 96930337T AT E331503 T1 ATE331503 T1 AT E331503T1
Authority
AT
Austria
Prior art keywords
tnf
alpha
necrosis factor
tumor necrosis
inhibiting drugs
Prior art date
Application number
AT96930337T
Other languages
English (en)
Inventor
Esther Shohami
Ruth Gallily
Raphael Mechoulam
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE331503T1 publication Critical patent/ATE331503T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96930337T 1995-09-11 1996-09-10 Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe ATE331503T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11524595A IL115245A (en) 1995-09-11 1995-09-11 Tumor necrosis factor inhibiting pharmaceuticals

Publications (1)

Publication Number Publication Date
ATE331503T1 true ATE331503T1 (de) 2006-07-15

Family

ID=11067971

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96930337T ATE331503T1 (de) 1995-09-11 1996-09-10 Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe

Country Status (9)

Country Link
US (3) US5932610A (de)
EP (1) EP0876143B1 (de)
JP (1) JP2000500737A (de)
AT (1) ATE331503T1 (de)
AU (1) AU708886B2 (de)
CA (1) CA2231764A1 (de)
DE (1) DE69636308T2 (de)
IL (1) IL115245A (de)
WO (1) WO1997011668A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
ATE247097T1 (de) * 1998-05-04 2003-08-15 Univ Connecticut Analgetische und immunomodulierende cannabinoiden
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
JP2002539246A (ja) 1999-03-22 2002-11-19 イミュジェン ファーマシューティカルズ インコーポレイティッド 免疫疾患の治療
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
DE60033834T2 (de) 1999-10-18 2007-11-15 The University Of Connecticut, Farmington Für periphäre cannabinoid-rezeptoren selektive liganden
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6943266B1 (en) 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6531128B1 (en) * 2000-02-08 2003-03-11 Pharmacia Corporation Methods for treating glaucoma
WO2001058469A1 (en) * 2000-02-08 2001-08-16 Wax Martin B Methods for treating glaucoma
EP1294699B1 (de) * 2000-05-12 2016-04-13 Genzyme Corporation Modulatoren des tnf-alpha-signalweges
EP1785417A3 (de) * 2000-06-22 2007-08-01 Pharmos Corporation Neuartige nicht-psychotrope Cannabinoide
KR20030008153A (ko) * 2000-06-22 2003-01-24 파모스 코포레이션 신규 비-향정신성 카나비노이드
US7235584B2 (en) * 2000-06-22 2007-06-26 Pharmos Corporation Non-psychotropic cannabinoids
US20020137802A1 (en) * 2000-09-28 2002-09-26 Travis Craig R. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
AU2002213429A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
US7329651B2 (en) * 2001-01-26 2008-02-12 University Of Connecticut Cannabimimetic ligands
EP1363632B1 (de) 2001-01-29 2010-08-25 The University of Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
KR20040023630A (ko) 2001-06-26 2004-03-18 아브게닉스, 인크. Ｏｐｇｌ에 결합하는 항체
AU2002320430A1 (en) * 2001-07-13 2003-01-29 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
CN1589269A (zh) * 2001-10-26 2005-03-02 康涅狄格大学 杂1,2－二氢化茚:一类新型有效的大麻配体
US20030232101A1 (en) * 2002-03-18 2003-12-18 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
IL148736A0 (en) * 2002-03-18 2002-09-12 Pharmos Corp Dexanabinol and dexanabinol analogs which regulate inflammation related genes
US20050137251A1 (en) * 2002-03-18 2005-06-23 Aaron Garzon Dexanabinol and dexanabinol analogs regulate inflammation related genes
WO2004017922A2 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
US20050192341A1 (en) * 2002-09-05 2005-09-01 Seth Kindler Non-psychotropic cannabinoids for prevention of cognitive impairment
WO2004047826A1 (en) * 2002-11-21 2004-06-10 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
ES2363914T3 (es) * 2002-11-21 2011-08-19 Genzyme Corporation Utilización de un derivado de diamida para inhibir el rechazo crónico de un transplante.
CA2507815A1 (en) * 2002-12-04 2004-06-17 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical compositions
CA2623723A1 (en) * 2005-09-29 2007-04-12 Amr Technology, Inc. Process for production of delta-9-tetrahydrocannabinol
WO2009059277A1 (en) * 2007-11-02 2009-05-07 University Of South Florida Synergistic modulation of microglial activation by nicotine and thc
GB0915877D0 (en) 2009-09-10 2009-10-14 E Therapeutics Plc Cancer cell apoptosis
GB201207305D0 (en) 2012-04-26 2012-06-13 E Therapeutics Plc Therapy
EP3160445B1 (de) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi-verwandte produkte und verfahren zur verwendung
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2017068349A1 (en) * 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80411A (en) * 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them
US5284867A (en) * 1989-11-07 1994-02-08 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-blocking pharmaceutical compositions
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
WO1994012667A1 (en) * 1992-11-27 1994-06-09 The United States Department Of The Army Inhibitors of arachidonic acid metabolites for preventing neurological damage

Also Published As

Publication number Publication date
WO1997011668A3 (en) 1997-05-15
US6331560B1 (en) 2001-12-18
EP0876143A4 (de) 2001-06-27
US20020049245A1 (en) 2002-04-25
DE69636308D1 (de) 2006-08-10
IL115245A0 (en) 1995-12-31
CA2231764A1 (en) 1997-04-03
US6545041B2 (en) 2003-04-08
AU6942096A (en) 1997-04-17
DE69636308T2 (de) 2007-05-31
EP0876143B1 (de) 2006-06-28
AU708886B2 (en) 1999-08-12
US5932610A (en) 1999-08-03
EP0876143A2 (de) 1998-11-11
WO1997011668A2 (en) 1997-04-03
IL115245A (en) 2002-12-01
JP2000500737A (ja) 2000-01-25

Similar Documents

Publication Publication Date Title
ATE331503T1 (de) Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe
EP0765160A4 (de)
EP1299374A4 (de) Neue nicht psychotropische cannabinoide
TW262461B (de)
GEP20043363B (en) Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
EA200100870A1 (ru) Композиции-ингибиторы циклооксигеназы-2 с быстро наступающим терапевтическим действием
EP3081214A3 (de) Zellnekrosehemmer
MY132705A (en) Novel compounds with analgesic effect
ES2160640T3 (es) Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos.
EP1674107A3 (de) Verwendung von Daptomycin
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
AU2905092A (en) Pharmaceutical dipeptide compositions and methods of use thereof
WO1999009000A3 (en) Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
RU2004135078A (ru) Травяная молекула как потенциальное противолейкозное лекарственное средство
EP0571597A4 (en) Method for treatment of acute and chronic painful arthropathic conditions in human and other mammals
WO2005004915A3 (en) Compositions comprising meloxicam
AU7385398A (en) Novel macrocyclic compounds as metalloprotease inhibitors
UA49789C2 (uk) Застосування димеру лізоциму як лікарського засобу для інгібування біосинтезу фактора некрозу пухлини, спосіб лікування та профілактики захворювань (варіанти), фармацевтична композиція (варіанти), застосування димеру лізоциму як лікарського засобу для профілактики або лікування сніду
BG103512A (en) Substituted pyramidine compounds and their application
DE602004006024D1 (de) Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose
EP0670165B1 (de) Verwendung der Seminalribonuklease als antimetastatische Verbindung
CA2392902A1 (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation
EP1785417A3 (de) Neuartige nicht-psychotrope Cannabinoide
EA199800372A1 (ru) Новые макроциклические соединения-ингибиторы

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties